1. Scrip
  2. >>R&D

Plazomicin’s US Debut Pencilled In For 2018, Achaogen Now Searching For Ex-US Partner

 
• By John Davis

Top-line results from the pivotal Phase III EPIC study, and the smaller CARE study in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) pathogens, should allow Achaogen to find an ex-US marketing partner and submit a US marketing application in 2017 for its potential new antibacterial, plazomicin, that could address a growing market opportunity in multidrug resistant infections.

South San Francisco biotech Achaogen Inc.has announced top-line Phase III results with its lead product, plazomicin, an engineered aminoglycoside, that it says puts it in a position potentially to offer a much needed new treatment option for serious multidrug-resistant bacterial infections.

The company believes plazomicin is unique in the way it has been engineered to make it resistant to aminoglycoside-modifying enzymes (AMEs) that can inactivate aminoglycosides and limit the use of this venerable class of antibacterials that includes streptomycin and tobramycin. Plazomicin also has a potent bactericidal activity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.